淋巴瘤细胞白血病临床研究

Clinical research on lymphosarcoma cell leukemia

目的:研究淋巴瘤细胞白血病发生率、疗效及预后等情况。方法:对331例淋巴瘤分析,33例合并淋巴瘤细胞白血病(LMCL),其中23例为中-高度恶性淋巴瘤。结果:LMCL91.54%为非霍奇金淋巴瘤中-高度恶性淋巴瘤占69.30%,LMCL治疗缓解率45.5%,1例行自体造血干细胞移植病人生存期2～18月,中位生存期5.2月。结论:淋巴瘤患者应常规行骨髓象检查,以尽早诊断LMCL,治疗选择新方案(包括造血干细胞移植)以提高疗效。

Objective To study the incidence,curative effect and prognosis of ly mphosarcoma cell leuke-mia.Methods To analyse 331 cases of lymphoma and 33 case s fall into LMCL ;23 cases among all the LMCL case belong to middle or high gra de lymphoma .Result 91.54%of LMCL belong to NHL while 69.30%of lymphoma is mid dle or high grade lymphoma .LMCL's remission rate is 45.50%.A case accepted aut ologous hemapoietic stem cell transplantation (AHSCT).The LMCL'S patient prolong ed life length range from 2 months to 18 months,and middle life span was 5.2 mo nths. Conclusion Cases with lymphosarcoma leukemia should receive bone marrow ex amination so that doctors can diagnose LMCL as early as possible and select new treatment methods (including HSCT) to improve effect.